77. Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens

BACKGROUND: The single-tablet regimen (STR) dolutegravir/rilpivirine (DTG/RPV) was approved in 2017 for use in virologically suppressed PWH, followed by approval in 2019 of dolutegravir/lamivudine (DTG/3TC). There is a need to evaluate outcomes of 2DR regimens in stable switch population by measurin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul, Eron, Joseph J, Radtchenko, Janna, Diaz-Cuervo, Helena, Moore, Mark, Santiago, Steven, Ramgopal, Moti, Mounzer, Karam, Elion, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644888/
http://dx.doi.org/10.1093/ofid/ofab466.077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644888/
http://dx.doi.org/10.1093/ofid/ofab466.077

Ejemplares similares